Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation-Reference-Cited by-同舟云学术

Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation

Published:2020-12 Issue:12 Volume:22 Page:755-761
ISSN:1465-3249
Container-title:Cytotherapy
language:en
Short-container-title:Cytotherapy

Author:

Chen Yu-Hong,Zhang Xian,Cheng Yi-Fei,Chen Huan,Mo Xiao-Dong,Yan Chen-Hua,Chen Yao,Han Wei,Sun Yu-Qian,Wang Yu,Zhang Xiao-Hui,Xu Lan-Ping,Liu Kai-Yan,Yang Junfang,Zhang Jianping,Zhang Gai-Ling,Shi Yanze,Su Yun-Chao,Li Wen-Qian,Xu Li,Song Dan,Zhang Min,Lu Peihua,Huang Xiao-Jun

Publisher

Elsevier BV

Subject

Cancer Research,Transplantation,Cell Biology,Genetics(clinical),Oncology,Immunology,Immunology and Allergy

Reference25 articles.

1. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia;Grupp;N Engl J Med,2013

2. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias;Brentjens;Blood,2011

3. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia;Davila;Sci Transl Med,2014

4. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial;Lee;Lancet,2015

5. Chimeric antigen receptor T cells for sustained remissions in leukemia;Maude;N Engl J Med,2014

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD19 CAR T cells for B cell malignancies: a systematic review and meta-analysis focused on clinical impacts of CAR structural domains, manufacturing conditions, cellular product, doses, patient’s age, and tumor types;BMC Cancer;2024-08-22

2. Donor-derived Anti-CD19 CAR T cells GC007g for relapsed or refractory B-cell acute lymphoblastic leukemia after allogeneic HSCT: a phase 1 trial;eClinicalMedicine;2024-01

3. Current assessment and management of measurable residual disease in patients with acute lymphoblastic leukemia in the setting of CAR-T-cell therapy;Chinese Medical Journal;2023-12-26

4. Differences in efficacy and safety among CAR-Ts anti-CD19/CD22, anti-CD19, and anti-CD22, in adult patients with relapse/refractory B-cell acute lymphoblastic leukemia: a meta-analysis and systematic review;Leukemia & Lymphoma;2023-08-07

5. Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a review;Leukemia & Lymphoma;2023-08